Valuation: Acadia Pharmaceuticals Inc.

Market Cap 2.96B 2.69B 2.48B 2.26B 4.24B 274B 4.45B 30.2B 12B 150B 11.1B 10.86B 469B P/E 2026 *
22.1x
P/E 2027 * 17.2x
Enterprise Value 1.96B 1.78B 1.64B 1.49B 2.8B 181B 2.95B 19.99B 7.94B 98.97B 7.34B 7.19B 311B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.19x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-2.73%
1 week-8.75%
Current month-16.90%
1 month-16.29%
3 months-41.08%
6 months-18.33%
Current year-35.94%
1 week 17.05
Extreme 17.05
19.44
1 month 15.86
Extreme 15.855
22.63
Current year 15.86
Extreme 15.855
30.96
1 year 15.86
Extreme 15.855
30.96
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
30/10/26 Sell

Chief Financial Officer

-3,321 0.0019%
06/08/26 Exercice

Chief Financial Officer

42,876 0.0250%
30/07/26 Sell

Chief Technology Officer

-16,558 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
-2.73%-8.75%-25.28%-25.35% 2.96B
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.51%-1.97%+27.77%+155.20% 40B
Weighted average by Cap. -1.49%-1.90%+31.73%+149.59%

Financials

2026 *2027 *
Net sales 1.28B 1.17B 1.08B 978M 1.83B 119B 1.93B 13.08B 5.2B 64.79B 4.81B 4.7B 203B 1.45B 1.32B 1.22B 1.11B 2.08B 135B 2.19B 14.85B 5.9B 73.52B 5.45B 5.34B 231B
Net income 136M 124M 114M 104M 195M 12.63B 205M 1.39B 554M 6.9B 512M 501M 21.65B 175M 159M 147M 133M 250M 16.18B 263M 1.78B 709M 8.84B 656M 642M 27.74B
Net Debt -1B -911M -839M -764M -1.43B -92.62B -1.51B -10.22B -4.06B -50.59B -3.75B -3.67B -159B -1.23B -1.12B -1.04B -942M -1.77B -114B -1.86B -12.6B -5.01B -62.41B -4.63B -4.53B -196B
Projected Income Statement - Annual - Acadia Pharmaceuticals Inc.
Logo Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
20/11/26 US$17.11 -2.73% 1,903,308
19/11/26 US$17.59 -1.35% 1,450,822
18/11/26 US$17.83 -2.67% 1,895,605
17/11/26 US$18.32 -1.87% 1,535,422
16/11/26 US$18.67 -0.43% 2,116,859
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Acadia Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
17.11USD
Average target price
30.21USD
Spread / Average Target
+76.57%
  1. Stock Market
  2. Stocks
  3. ACAD Stock